2022
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.
Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, de Castro CM, Deeg HJ, DeZern AE, Dinner S, Foucar C, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Jonas BA, Keel S, Madanat Y, Maness LJ, Mangan J, McCurdy S, McMahon C, Patel B, Reddy VV, Sallman DA, Shallis R, Shami PJ, Thota S, Varshavsky-Yanovsky AN, Westervelt P, Hollinger E, Shead DA, Hochstetler C. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. Journal Of The National Comprehensive Cancer Network 2022, 20: 106-117. PMID: 35130502, DOI: 10.6004/jnccn.2022.0009.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeNCCN guidelinesHigh-risk myelodysplastic syndromeNCCN Guidelines InsightsSupportive care recommendationsManagement of patientsClinical evidencePrognostic significanceTreatment recommendationsCare recommendationsMultidisciplinary panelHigh-risk assessmentPredisposition syndromeBiologic factorsSyndromeMDS expertsGuidelinesImportant advancesPatientsRecommendationsTherapyDiagnosis
2017
Day 14 bone marrow examination in the management of acute myeloid leukemia
Terry CM, Shallis RM, Estey E, Lim SH. Day 14 bone marrow examination in the management of acute myeloid leukemia. American Journal Of Hematology 2017, 92: 1079-1084. PMID: 28612456, DOI: 10.1002/ajh.24818.Peer-Reviewed Original ResearchConceptsDay 14 bone marrowBlast cell countNational Comprehensive Cancer NetworkBone marrow examinationInduction therapyBone marrowCell countMarrow examinationSecond induction therapyLonger hospital stayTreatment-related mortalityComprehensive Cancer NetworkManagement of patientsBone marrow evaluationAcute myeloid leukemiaFurther chemotherapyComplete remissionHospital stayIntravenous antimicrobialsMarrow evaluationClinical trialsBlood productsMyeloid leukemiaHigh riskDay 28